|
ARCHIVES | CONTACT
| SERVICES
|
HOME |
||
|
Company Name |
|
|
December 31, 2018 Issue |
||
|
CEOCFO MAGAZINE |
||
|
|
||
|
IT Procurement, Asset Management Solutions and Equipment Leasing and Financing for Large Global Corporations |
||
|
Relevium Technologies combines eCommerce with Science and Formulation
Partners, through Existing Brands to leverage Unique Health Benefits from
Cannabis and Nutraceutical Products Q&A with Aurelio Useche, Director and CEO and Abis Hussain, Chief Marketing Officer
Aurelio Useche Director and CEO
Relevium Technologies (TSX Venture: RLV) (OTCQB: RLLV)
Interview conducted by: Bud Wayne Editorial Executive, CEOCFO Magazine, Published – August 13, 2018
CEOCFO: Mr. Useche, would you tell us the focus of Relevium Technologies today, how long have you been with the company and what attracted you? Mr. Useche: The initial strategy of Relevium was to consolidate the health and wellness space in eCommerce. We found that there were a lot of entrepreneurial brands that cater to that marketplace, whether it is nutrition, supplements or skincare that only sell their products online. We identified a pipeline of businesses between $2 and $20 million of revenue, highly profitable, running with an EBITDA of 20% to 30% and we saw a real opportunity to consolidate brands and create value. We acquired our first company last year around this same time of the year, Bioganix, which is an online brand of nutraceutical products. Ever since, we are adding value by focusing on brand development, product extension, geographic expansion and marketplace diversification. We are currently expanding our brand to the European market, which we anticipate launching this month. We have expanded the product line through the introduction of trending products and through partnerships that provide exclusivity through science-based ingredients and formulations. One of our main strengths is our ability to forge different partnerships. In the case of Bioganix we forged a couple partnerships with companies that can provide us with a specificity in formulation services for our products to have a lot of medical research behind them, so we could then launch products that are a little bit different from what we are seeing out there.
I have been with the company as CEO since November 2016 and in addition to being an investor in the IPO, my initial attraction was the opportunities in the health and wellness market.
CEOCFO: Was Bioganix an acquisition or is that an outfit you are partnering with? Mr. Useche: It was 100% acquisition.
CEOCFO: Are you partnering with people to deliver the products to market? Mr. Useche: This is in fact a key value-added focus to our strategy. We know our strengths in the digital space and we seek to partner with organizations that provide unique and trusted ingredients as well as formulation capabilities. When we acquire a new brand, we focus on the introduction of exclusive products that can be introduced directly into the channel. The fact that these are exclusive formulations translates quickly into higher margins and lower media buying costs. One of such partners is Tersus Life Sciences, a supplement company located in Bonita Springs, Florida that developed the science behind Provinal®–an ultra-purified form of Omega 7 (Palmitoleic acid), the next generation of Omega fatty acids that have been shown to possess broad properties to combat diabetes, metabolic syndrome, and atherosclerosis. We are currently in production of two exclusive formulations, one that supports the most important markers of cardiac health and another that supports overall eye health.
Last year we started looking at the health benefits of cannabinoids and at the possibility of developing new formulations. Our initial approach was strictly from a health support and science point of view and not as a strategy for capital markets promotion. This was the how our team began to focus on the potential health supporting cannabis market.
One of the challenges we faced in the exploration process, in addition to regulatory issues in the US and Canada, was the supply chain. The marketplace is currently flooded with hundreds if not thousands of unproven products without any traceability on the quality and source of the key ingredients. Although we do not consider ourselves to be a “Cannabis Company”, we do believe that cannabinoids will provide our customers with added health benefits to address things like inflammation, pain, anxiety and even sports recovery.
In view of these quality and sourcing challenges we decided to create our subsidiary Biocannabix Health Corporation, a vertically integrated, science-based developer of nutraceutical and other medical grade consumer products focused specifically on the cannabinoid market. We are currently cementing the right partnerships to ensure that Biocannabix becomes a leading consumer health product company in the space.
This is where we are today. We remain focused in growing our online brand portfolio through acquisitions in our core business and we are also working hard to build Biocannabix into a fully integrated cannabis company that would grow, process and develop consumer packaged goods for medical purposes.
“The value that we add is
that we are very focused on eCommerce and digital marketing and quicker and
more effective ways to launch new products… We believe that we can add a lot
of value leveraging the go-to-market effectives of online business to build
brand equity and then combine this with brick and mortar.”- Aurelio Useche |
VIDEO or PRESENTATION “TCGi is excited to launch our own Procure-to-Pay platform in September that will deliver end-to-end automation of our workflows for our team, customers and all the stakeholders with whom we partner. This will be a game-changer for TCGi!”- Avis Yates Rivers
Verifi Inc.
Contact: Matthew Katz 323-655-5787
google plus press releases news - events
|
|
|
disclaimers |
||
|
|
||
|
|
||
|
|
||
